Cancer-related cachexia and oxidative stress: beyond current therapeutic options

References

• Heber D, Byerley LO, Chi J. Pathophysiology of malnutrition in the adult cancer patient. Cancer 58(8), 1867–1873 (1986).
   Google Scholar
• Bruera E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 49(2), 35–42 (1992).
   Google Scholar
• Brennan MR. Uncomplicated starvation versus cancer cachexia. Cancer Res. 37(7), 2359–2364 (1977).
   Google Scholar
• Nelson K, Walsh D. Management of the anorexia/cachexia syndrome. Cancer Bull 43, 403–406 (1991).
   Google Scholar
• Tisdale MJ. Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition 13(1), 1–7 (1997).
   Google Scholar
• •Important study demonstrating the connections between metabolic alterations and clinical symptoms.
   Google Scholar
• Bruera E. ABC of palliative care. Anorexia, cachexia and nutrition. BE Med. J. 315(7117),1219-1222 (1997). Describes anorexia and cachexia in the context of malnutrition syndromes.
   Google Scholar
• Devereaux DF, Redgrave TG, Tilton M et al Intolerance to administered lipids in tumor bearing animals. Surgery100, 292–297 (1984).
   Google Scholar
• Vlassara H, Spiegel RJ, San Doval D, Cerami A. Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Holm. Metab. Res. 18(10), 698–703 (1986).
   Google Scholar
• Moldawer LL, Gelin J, Schersten T, Lundholm KG. Circulating interleukin-1 and tumor necrosis factor during inflammation. Am jPhjsiai 253(6), R922—R928 (1987).
   Google Scholar
• Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin-6 in experimental cancer cachexia. Clin. Invest. 89(5), 1681–1684 (1992).
   Google Scholar
• Busbridge J, Dascombe MJ, Hoopkins S. Acute central effects of interleukin-6 on body temperature, thermogenesis and food intake in the rat. Proc. Nutr Sac 38, 48A (1989).
   Google Scholar
• Gelin J, Moldawer LL, Lonnroth C, Sherry B, Chizzonite R, Lundholm K Role of endogenous tumor necrosis factor-CL and interleukin-1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 51(1), 415–421 (1991).
   Google Scholar
• McLaughlin CL, Rogan GJ, Tou J, Baile CA, Joy WD. Food intake and body temperature responses of rat to recombinant interleukin-l3 and a tripeptide interleukin-10 antagonist. Physiol. Behav. 52(6), 1155–1160 (1992).
   Google Scholar
• Noguchi Y, Yoshikawa T, Matsumoto A, Svaninger G, Gelin J. Are cytokines possible mediators of cancer cachexia? Surg. Today26(7), 467–475 (1996).
   Google Scholar
• Sherry BA, Gelin J, Fong Y. Anticachectin/tumor necrosis factor-CL antibodies attenuate development of cancer cachexia. Cancer Res. 51,415–421 (1991).
   Google Scholar
• Matthys P, Billiau A. Cytokines and cachexia. Nutrition 13 (9), 763–770 (1997).
   PubMed Web of Science ®Google Scholar
• Cavalli G, Goldhirsch A, Jungi F et al Randomized trial of low- versus high-dose medroxyprogesterone acetate in the treatment of postmenopausal patients with advanced breast cancer. In: Role of medmxyprogesterone in endocrine-related tumors. Pellegrini A, Robustelli Della Cuna G (Eds). Raven Press, NY, USA 79–89 (1984).
   Google Scholar
• Tchekmedyian NS, Tait N, Moody M, Aisner J. High-dose megestrol acetate: a possible treatment for cachexia. JAIVIA 257(9), 1195–1198 (1987).
   Google Scholar
• McCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur j Pharmacol 265(1-2), 99–102 (1994).
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccià A, Bianchi A et al Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. int. j Clin. Lab. Res. 25(3), 135–141 (1995).
   Google Scholar
• Mantovani G, Maccià A, Esu S et al Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur. j Cancer 33(4), 602–607 (1997). Describes the role of progestins in reducing the production of cytokines, suggesting potential rationale for their clinical use.
   Google Scholar
• Mantovani G, Maccià A, Lai P et al Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Sernin. Oncol 2 (Suppl. 6), 45–52 (1998).
   Google Scholar
• Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 61 (4), 499–514 (2001).
   PubMed Web of Science ®Google Scholar
• ••Exhaustively deals with the management of cancer-related anorexia/cachexia (CACS).
   Google Scholar
• Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 55(5), 675–688 (1998). Important review on the treatment approach to cachexia.
   Google Scholar
• Simons JPFHA, Aaronson NK, Vansteenkiste JF et al Effect of medroxyprogesterone acetate on appetite, weight and quality of life in advanced-stage nonhormone-sensitive cancer: a placebo-controlled multicenter study. j Clin. Oncol 14(4), 1077–1084 (1996).
   Google Scholar
• Ottery FD, Walsh D, Strawford A. Pharmacologic management of anorexia/cachexia. Semin. Oncol 25(2) (Suppl. 6), 35–44 (1998).
   Google Scholar
• De Vita VT Jr, Hellman S, Rosenberg SA. Cancer principles and practice of oncology 5th edition. Lippincott-Raven Publishers, Philadelphia, PA, USA (1997).
   Google Scholar
• Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. j Pain Symptom Manage. 9(7), 442–445 (1994).
   Google Scholar
• Fuinsinger R. Pharmacological approach to cancer anorexia and cachexia. In: Cachexia-anorexia in cancer patients. Bruera E, Higginson I (Eds). Oxford University Press, Oxford, UK, 128–140 (1996).
   Google Scholar
• Plata-Salaman CR. Dexamethasone inhibits food intake suppression induced by low doses of interleukin-10 administered intracerebroventricularly. Brain Res. Bull. 27(5), 737–738 (1991).
   Google Scholar
• Uehara A, Sekiya C, Takasugi Y, Namiki M, Arimura A. Anorexia induced by interleukin-1: involvement of corticotropin-releasing factor. Am. j Physiol 257(3), R613—R617 (1989).
   Google Scholar
• Han J, Thompson P, Beutler B. Dexamethasone and pentoxyfylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 172(1), 391–394 (1990).
   Google Scholar
• Wigmore SJ, Falconer JS, Plester CE et al Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br. Cancer72(1), 185–188 (1995).
   Google Scholar
• McMillan DC, O'Gorman P, Fearon KC, McArdle CS. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br.Cancer 76 (6), 788–790 (1997) .
   Google Scholar
• Lundholm K, Gelin J, Hyltander A et al Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 54(21), 5602–5606 (1994).
   Google Scholar
• Masferrer JL, Leahy KM, Koki AT et al Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60(5), 1306–1311 (2000).
   Google Scholar
• Reddy BS, Hirose Y, Lubet R et al Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60(2), 293–297 (2000).
   Google Scholar
• Lissoni P, Paolorossi F, Tancini G et al Is there a role for melatonin in the treatment of neoplastic cachexia? Eur j Cancer
   Google Scholar
• A(8), 1340–1343 (1996).
   Google Scholar
• Lissoni P, Barni S, Tancini G et al Role of the pineal gland in he control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-CL and the pineal hormone melatonin. j Biol. Regul Homeost. Agents 8 (4), 126–129 (1994) .
   Google Scholar
• Purasiri P, Murray A, Richardson S, Heys SD, Horrobin D, Eremin 0. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin. Sci. 87(6), 711–717 (1994).
   Google Scholar
• Wigmore SJ, Ross JA, Falconer JS et al The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12(1), S27—S30 (1996).
   Google Scholar
• Wigmore SJ, Fearon KC, Maingay JP, Ross JA. Downregulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosopentaenoic acid is mediated via suppression of interleukin-6. Clin. Li. 92 (2), 215–221 (1997) . Describes the effect of eicosapentaenoic acid in CACS through supression of proinflamrnatory cytokines.
   Google Scholar
• Carbo N, Lopez-Soriano J, Tarrago T et al Comparative effects of 02-adrenergic agonists on muscle waste associated with tumor growth. Cancer Lett. 115(1), 113–118 (1997).
   Google Scholar
• Hoffman RJ, Hoffman RS, Freyberg CL et al Clenbuterol ingestion causing prolonged tachycardia, hypokalemia and hypophosphatemia with confirmation by quantitative levels. j Toxicol Clin. Toxic& 39(4), 339–344 (2001).
   Google Scholar
• ••
   Google Scholar
• Ziegler TR, Wilmore DW. Anabolic effects of growth hormone administration in adults. In: Growth hormone and somatomedins during lifespan. Muller EE, Cocchi D, Locatelli V (Eds). Springer-Verlag, Berlin, Germany, 312–328 (1993).
   Google Scholar
• Froesch ER, Schmid C, Schwander J, Zapf J. Actions of insulin-like growth factors. Ann. Rev Physiol 47,443–467 (1985).
   PubMed Web of Science ®Google Scholar
• Tayek JA, Brasel JA. Failure of anabolism in malnourished cancer patients receiving growth hormone: a clinical research center study. .1. Clin. Endocrinol Metab. 80(7), 2082–2087 (1995).
   Google Scholar
• Ottery FD. Supportive nutritional management of the patient with pancreatic cancer. Oncology10\(Suppl. 9), 26–32 (1996).
   Google Scholar
• Argiles JM, Meijsing SH, Pallares-Trujillo J, Guirao X, Lopez-Soriano FJ. Cancer cachexia: a therapeutic approach. Med. Res. Rev 21(1), 83–101 (2001).
   Google Scholar
• ••Reviews the most important therapeuticapproaches to CACS.
   Google Scholar
• Cangiano C, Laviano A, Meguid MM et al Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. j Natl Cancer Inst. 88(8), 550–552 (1996).
   Google Scholar
• •Describes the role of branched-chain amino acids in CACS
   Google Scholar
• Gutierrez-Rodriguez 0. Thalidomide: a promising new treatment for rheumatoid arthritis. Arthritis Rheum. 27(10), 1118–1121 (1984).
   Google Scholar
• Atra S, Sato El. Treatment of cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin. Exp. Rheumatol. 11(5), 487–493 (1993).
   Google Scholar
• Vogelzang GB, Farmer ER, Hess AD et al. Thalidomide for the treatment of chronic graft versus host disease. N Engl. I Med. 326(16), 1055–1058 (1992).
   Google Scholar
• Tramontana JM, Utaipat U, Molloy A et al Thalidomide treatment reduces tumor necrosis factor-CL and enhances virus Type 1 and M. tuberculosis infection. I Acquit: Immune Defic. Syndr. Hum. Retrovirol 11(3), 247–257 (1996).
   Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc. Nati Acad. Sri. USA 91, 4082–4085 (1994).
   PubMed Web of Science ®Google Scholar
• Minchinton Al, Fryer IKH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs7(3), 339–343 (1996).
   Google Scholar
• Gutman M, Szold A, Ravid A, Lazauskas T, Merimsky 0, Klausner JM. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res. 16(6B), 3673–3677 (1996).
   Google Scholar
• Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism and antioxidant functions. Grit. Rev Food Sri. Nutt: 43(1), 89–143 (2003).
   Google Scholar
• Mantovani G, Maccio A, Melis G, Mura L, Massa E, Mudu MC. Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants a-lipoic acid and N-acetyl cysteine. hit. j Cancer86 (6), 842–847 (2000).
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccio A, Madeddu C et al Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. hit. j Cancer 98(1), 84–91 (2002).
   Google Scholar
• Mantovani G, Maccio A, Madeddu C et al The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic. Res. 37(2), 213–223 (2003).
   Google Scholar
• Schwartz MW, Dallman ME, Woods SC. Hypothalamic response to starvation: implications for the study of wasting disorders. Am. j Physiol 269(5), 949–957 (1995).
   Google Scholar
• Schwartz MW, Seeley RJ. Neuroendocrine responses to starvation and weight loss. NEngl.J. Med. 336(25), 1802–1811 (1997).
   Google Scholar
• Inui A. Feeding and bodyweight regulation by hypothalamic neuropeptides: mediation of the actions of leptin. Trends Neurosci. 22(2), 62–67 (1999).
   Google Scholar
• Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res. 61(4), 1432–1438 (2001).
   PubMed Web of Science ®Google Scholar
• Ahima RS, Prabakaran D, Mantzoros C et al. Role of leptin in the neuroendocrine response to fasting. Nature 382(6588), 250–252 (1996).
   PubMed Web of Science ®Google Scholar
• Nelson KA. The cancer anorexia-cachexia syndrome. Semin. Oncol 27(1), 64–68 (2000).
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA et al Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. j Clin. Oncol 17(10), 3299–3306 (1999).
   Google Scholar
• Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Grit. Rev. Oncol Hematol 34(3), 137–168 (2000).
   Google Scholar
• Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 59(18), 4493–4501 (1999).
   Google Scholar
• ••One of the most important and exhaustivereviews covering all aspects of CACS from pathogenesis to treatment approach.
   Google Scholar
• Kotler DR Cachexia. Ann. Intern. Med. 133(8), 622–634 (2000).
   Google Scholar
• MacDonald N. Cachexia-anorexia workshop: introduction. Nutrition 16(10),
   Google Scholar
• -1008 (2000).
   Google Scholar
• Lechan RM, Tatro JB. Hypothalamic melanocortin signaling in cachexia. Endocrinology142(8), 3288–3291 (2001).
   Google Scholar
• Argiles JM, Meijsing SH, Pallares-Trujillo J, Guirao X, Lopez-Soriano FJ. Cancer cachexia: a therapeutic approach. Med. Res. Rev 21(1), 83–101 (2001).
   Google Scholar
• Asakawa A, Inui A, Kaga T et al Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Castroentemlogy120 (2), 337–345 (2001).
   PubMed Web of Science ®Google Scholar
• Inui A. Ghrelin. An orexigenic and somatotrophic signal from the stomach. Nat. Rev Neurosci. 2(8), 551–560 (2001).
   Google Scholar
• •Exhaustively describes the mechanism of action of ghrelin, one of the hormones involved in the regulation of food intake.
   Google Scholar